**Background**
Advanced glycation end products (AGEs) are formed through the non-enzymatic glycation of proteins and lipids, a process significantly accelerated in hyperglycemic conditions such as diabetes mellitus. The accumulation of AGEs and their interaction with the receptor for AGEs (RAGE) contribute to chronic inflammation, oxidative stress, and tissue fibrosis, leading to severe complications including diabetic nephropathy and cardiovascular disease. Targeting the formation and accumulation of these products is a critical strategy for mitigating diabetic complications. In this context, we will introduce an advanced glycation end product inhibitor – Alagebrium.
**Definition**
Alagebrium chloride (ALT711) is a small molecule inhibitor of advanced glycation end products (AGEs) with the molecular formula C13H14ClNOS.
**In Vitro and In Vivo Studies**
According to the Alagebrium description, this compound acts as a potent AGE inhibitor. In terms of Alagebrium in vitro activity, studies have demonstrated that endothelial cell (EC) proliferation is increased in all groups receiving Alagebrium, particularly when cells are seeded on matrix derived from the ascending aorta (AAo) of obese (ZO) and diabetic (ZD) rats.
Regarding Alagebrium In Vivo efficacy, treatment in diabetic RAGE apoE double-KO mice is associated with a modest reduction in renal mass and a decrease in hyperfiltration compared to untreated controls. Furthermore, Alagebrium treatment in these mice leads to a further reduction in glomerular collagen IV levels, bringing them closer to the levels observed in control mice. In obese and diabetic rat models, Alagebrium increases blood flow in ZO rats and reduces distal vascular resistance in ZD rats. Additionally, a decrease in neointimal hyperplasia (NH) intrastrut thickness as a function of local radius is observed across all treated groups, and a significant increase in TGF-β expression is found in the AAo of treated ZL rats. Notably, treatment with Alagebrium does not affect blood pressure, heart rate, or body weight in ZL, ZO, or ZD groups. For researchers seeking detailed Alagebrium technical information, these results highlight its potential in reducing glomerular fibrogenesis and inhibiting neointimal hyperplasia. In conclusion, Alagebrium is an AGE inhibitor that provides protective effects against diabetic renal and vascular damage.
Keywords
Alagebrium, 341028-37-3, ALT711, ALT 711, ALT-711, Endogenous Metabolite, Inhibitor, inhibitor, inhibit
References
[1] Watson AM, et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGEactivation in diabetic apolipoprotein E knockout mice. Diabetes. 2012 Aug;61(8):2105-13.
[2] Wang H, et al. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats. Am J Physiol Heart Circ Physiol. 2015 Oct;309(7):H1130-40.